Skip to main content
padlock icon - secure page this page is secure

Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11)

Buy Article:

$42.00 + tax (Refund Policy)

Parthenolide, the principal bio-active component of the herb feverfew (Tanacetum parthenium), has shown anti-leukemic activity. We evaluated the cell cycle status and the phosphorylation/activation of proteins involved in signal transduction in t(4;11) and non-t(4;11) acute lymphoblastic leukemia (ALL) cell lines after treatment with parthenolide. The cells were treated with the vehicle or 10 ┬ÁM parthenolide for 2, 4, 6 and 8 h. As shown by flow cytometric analysis, parthenolide induced growth arrest at the S to G2/M phase transition. Using multiplex technology and Western blotting, we showed that the treatment with parthenolide within 0 to 10 h induced the phosphorylation of stress signaling proteins, including the p38 mitogen-activated protein kinase, the c-Jun N-terminal kinase, c-Jun, the heat shock protein 27 and protein kinase B. These data show that parthenolide induces a stress response leading to cell death and provide further evidence suggesting that parthenolide could be useful as a novel therapeutic agent against high risk ALL with chromosomal translocation t(4;11).
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: United States Department of Agriculture, Western Human Nutrition Research Center, University of California, Davis, CA 95616, USA., Email: [email protected]

Publication date: November 1, 2010

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more